Phase 4
Completed N=133
Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
Source: ClinicalTrials.gov NCT00883675 ↗Enrolled (actual)
133
Serious AEs
10.5%
Results posted
Dec 2013
Primary outcomePrimary: Febrile Neutropenia — 12 participants
Summary
The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Febrile Neutropenia |
12 | — |
Eligibility Criteria
Inclusion Criteria
- Non-small cell lung cancer stage IB - IIIA, complete resection with mediastinal lymph node dissection
- ECOG status 0-1
- >14 and grade 1
- Concurrent other malignancies, other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
- Medical condition that will not permit treatment or follow up according to the protocol
- Prior treatment with docetaxel or carboplatin
- Hypersensitivity to polysorbate 80, platinum-containing compounds or mannitol
- Treatment with other investigational anti-cancer drugs within 30 days of registration
- Pregnant or nursing women
- HIV-positive patients
Data sourced from ClinicalTrials.gov (NCT00883675). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.